Spots Global Cancer Trial Database for A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
Official Title: A Multi-center, Randomized, Phase 3 Study of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen for Patients With Relapsed or Transformed Follicular Non-Hodgkin's Lymphoma
Study ID: NCT00319332
Study Description
Brief Summary: This is a multi-center, randomized, study to compare Iodine I 131 Tositumomab therapeutic regimen to Ibritumomab Tiuxetan therapeutic regimen in the treatment of patients with relapsed or transformed follicular non-Hodgkin's B-cell lymphoma. A total of 350 patients, approximately 175 patients per arm, will be enrolled at 30 to 40 sites in the United States.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Clinical Trials Call Center, Iowa City, Iowa, United States
GSK Clinical Trial Call Center, St. Louis, Missouri, United States
GSK Clinical Trials Call Center, Buffalo, New York, United States
GSK Clinical Trials Call Center, Charleston, North Carolina, United States
GSK Clinical Trial Call Center, Portland, Oregon, United States
GSK Clinical Trial Call Center, Knoxville, Tennessee, United States
GSK Clinical Trial Call Center, Seattle, Washington, United States
GSK Clinical Trials Call Center, Tacoma, Washington, United States
Contact Details
Name: GSK Clinical Trials, MD
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
